WallStreetZenWallStreetZen

NASDAQ: AVTE
Aerovate Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Analyst price target for AVTE

Based on 2 analysts offering 12 month price targets for Aerovate Therapeutics Inc.
Min Forecast
$27.00+24.6%
Avg Forecast
$31.50+45.36%
Max Forecast
$36.00+66.13%

Should I buy or sell AVTE stock?

Based on 2 analysts offering ratings for Aerovate Therapeutics Inc.
Strong Buy
Strong Buy
2 analysts 100%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their AVTE stock forecasts and price targets.

AVTE stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
Guggenheim
Top 5%
96
Strong BuyInitiates Coverage On$36.00+66.13%2023-03-01
BTIG
Top 14%
87
Strong BuyUpgrades$27.00+24.60%2022-12-06

1 of 1

Forecast return on equity

Is AVTE forecast to generate an efficient return?
Company
N/A
Industry
-0.01%
Market
28.77%

Forecast return on assets

Is AVTE forecast to generate an efficient return on assets?
Company
N/A
Industry
0.05%

AVTE earnings per share forecast

What is AVTE's earnings per share in the next 3 years based on estimates from 3 analysts?
Avg 1 year Forecast
-$2.10
Avg 2 year Forecast
-$2.05
Avg 3 year Forecast
-$3.39

AVTE revenue forecast

What is AVTE's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$36.7M
Avg 2 year Forecast
$129.1M
Avg 3 year Forecast
$323.8M

AVTE vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
AVTE$21.67$31.50+45.36%Strong Buy
ALDX$9.06$18.67+106.04%Strong Buy
TRDA$16.20$18.00+11.11%Hold
BTAI$18.25$42.17+131.05%Buy
MOR$3.94$15.00+280.71%Buy
View Top Biotech Stocks

Aerovate Therapeutics Stock Forecast FAQ

Is Aerovate Therapeutics Stock a good buy in 2023, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: AVTE) stock is to Strong Buy AVTE stock.

Out of 2 analysts, 2 (100%) are recommending AVTE as a Strong Buy, 0 (0%) are recommending AVTE as a Buy, 0 (0%) are recommending AVTE as a Hold, 0 (0%) are recommending AVTE as a Sell, and 0 (0%) are recommending AVTE as a Strong Sell.

If you're new to stock investing, here's how to buy Aerovate Therapeutics stock.

What is AVTE's earnings growth forecast for 2023-2025?

(NASDAQ: AVTE) Aerovate Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.35%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 19.49%.

Aerovate Therapeutics's earnings in 2023 is -$44,712,000.On average, 3 Wall Street analysts forecast AVTE's earnings for 2023 to be -$51,670,653, with the lowest AVTE earnings forecast at -$54,377,211, and the highest AVTE earnings forecast at -$48,718,045. On average, 2 Wall Street analysts forecast AVTE's earnings for 2024 to be -$50,440,400, with the lowest AVTE earnings forecast at -$51,916,704, and the highest AVTE earnings forecast at -$48,718,045.

In 2025, AVTE is forecast to generate -$83,411,197 in earnings, with the lowest earnings forecast at -$100,880,799 and the highest earnings forecast at -$65,941,596.

What is AVTE's revenue growth forecast for 2026-2028?

(NASDAQ: AVTE) Aerovate Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 40.36%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 8.8%.

Aerovate Therapeutics's revenue in 2023 is $0.On average, 1 Wall Street analysts forecast AVTE's revenue for 2026 to be $903,498,281, with the lowest AVTE revenue forecast at $903,498,281, and the highest AVTE revenue forecast at $903,498,281. On average, 2 Wall Street analysts forecast AVTE's revenue for 2027 to be $3,177,105,446, with the lowest AVTE revenue forecast at $2,338,958,239, and the highest AVTE revenue forecast at $4,015,277,258.

In 2028, AVTE is forecast to generate $7,966,138,434 in revenue, with the lowest revenue forecast at $4,005,213,783 and the highest revenue forecast at $11,927,063,086.

What is AVTE's forecast return on assets (ROA) for 2023-2026?

(NASDAQ: AVTE) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 0.05%.

What is AVTE's Price Target?

According to 2 Wall Street analysts that have issued a 1 year AVTE price target, the average AVTE price target is $31.50, with the highest AVTE stock price forecast at $36.00 and the lowest AVTE stock price forecast at $27.00.

On average, Wall Street analysts predict that Aerovate Therapeutics's share price could reach $31.50 by Mar 1, 2024. The average Aerovate Therapeutics stock price prediction forecasts a potential upside of 45.36% from the current AVTE share price of $21.67.

What is AVTE's Earnings Per Share (EPS) forecast for 2023-2025?

(NASDAQ: AVTE) Aerovate Therapeutics's current Earnings Per Share (EPS) is -$1.57. On average, analysts forecast that AVTE's EPS will be -$2.10 for 2023, with the lowest EPS forecast at -$2.21, and the highest EPS forecast at -$1.98. On average, analysts forecast that AVTE's EPS will be -$2.05 for 2024, with the lowest EPS forecast at -$2.11, and the highest EPS forecast at -$1.98. In 2025, AVTE's EPS is forecast to hit -$3.39 (min: -$4.10, max: -$2.68).

What is AVTE's forecast return on equity (ROE) for 2023-2026?

(NASDAQ: AVTE) forecast ROE is N/A, which is considered weak.
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTube
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.